Statement of deviation or variation in the use of proceeds of Rights Issue for the Quarter ended 30th June, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genpharmasec Ltd has filed a quarterly statement confirming there is no deviation or variation in the use of proceeds from its Rights Issue. The company had raised Rs. 4,845.05 Lakhs through the Rights Issue allotted on 21 February 2024. The funds were allocated across five objects: acquiring equity shares in Derren Healthcare to make it a subsidiary (Rs. 1,443.58 Lakhs), repaying borrowings (Rs. 588.00 Lakhs), working capital (Rs. 1,650.00 Lakhs), general corporate purposes (Rs. 1,138.47 Lakhs), and issue expenses (Rs. 25.00 Lakhs). As of 30 June 2025, the company has utilised approximately Rs. 4,536.91 Lakhs, with the borrowing repayment object showing partial utilisation (Rs. 286.00 Lakhs out of Rs. 588.00 Lakhs). The Audit Committee and auditors had no comments, and no monitoring agency was applicable.
This is a routine compliance filing confirming funds are being used as originally disclosed to shareholders. No negative impact on shareholders; the partial utilisation of the borrowing repayment allocation is disclosed transparently and is not flagged as a deviation.